We are working to expand our portfolio and are close to achieving further milestones in our new indication area for EDOR® test – depression relapse. 200309 - Emotra - PM - Emotra close to sealing collaboration agreement for clinical studies
This March, Emotra AB (“Emotra”) will be presenting the Company as well as our present situation, goals and strategy to create a new market for EDOR test in the psychiatric care sector. 200303- Emotra - News letter - Emotra participates in the Mangold Insight...
(Correction: This correction regards a mistake in the terms for subscription warrants; the correct terms are stated below under “Summary of terms for subscription warrants”) 200224 - Emotra- PM - Issue resolution FINAL_Correction_clean
Correction: Emotra’s Year-end report for 2019 stated the wrong publication date for our interim report for the first quarter 2020. The correct date is May 29, 2020. 200226 - Emotra - PM - Correction regarding our Q1 2020 report
The Board and CEO of Emotra AB herewith present the year-end report for the financial year 2019. 200221- Year-end report 2019
Today, February 24, 2020, EMOTRA AB (“Emotra” or the “Company”) announced that the Board has decided to carry out a rights issue comprising a maximum of 8,796,586 units. 200224 - Emotra- PM - Issue resolution
Due to the trading volumes seen in shares in Emotra and the large share price rise in its wake, the Company feels compelled to comment the situation. 200212 - Emotra - PM - Emotra comments on share trade volumes and the share price rise
The Company is now taking an important first step for the new indication area for EDOR® Test – depression relapse. 200206 - Emotra - PM - Emotra signs agreement for research collaboration
At the end of 2019, Emotra AB (“Emotra”) were interviewed by the management team at AstraZeneca BioVentureHub, after which we were offered space at the pharmaceutical company’s research facility in Mölndal, Sweden. 200130- Emotra - Newsletter - New office and...
Lately, Lars-Håkan Thorell from Emotra AB (“Emotra”) has been presenting the fundamental biological mechanisms behind hyporeactivity at various scientific symposiums. 191127 - Emotra -PM - Lectures
